150 results
8-K
EX-2.2
ORTX
Orchard Therapeutics plc
24 Jan 24
Termination of a Material Definitive Agreement
4:17pm
into account its safety, tolerability and efficacy, its proprietary position and profitability (including pricing and reimbursement status), projected
DEFA14A
ORTX
Orchard Therapeutics plc
30 Nov 23
Additional proxy soliciting materials
4:13pm
registrational trial in December to evaluate the efficacy and safety of OTL-203 compared to allogeneic HSCT.”
OTL-203 has previously received Rare Pediatric … generally well-tolerated with a safety profile consistent with the selected conditioning regimen. The viral vector integration profile was consistent
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
30 Nov 23
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
4:06pm
to initiating our global registrational trial in December to evaluate the efficacy and safety of OTL-203 compared to allogeneic HSCT.”
OTL-203 has … , treatment with OTL-203 has been generally well-tolerated with a safety profile consistent with the selected conditioning regimen. The viral vector
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
or severity of any previously identified side effects, adverse effects, adverse events or safety observations or reports of new side effects, adverse … effects, adverse events or safety observations, in each of (A) – (F), solely to the extent not resulting from or arising out of any wrongdoing, fraud
8-K
EX-99.1
ked0l
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am
PREM14A
v2yijph jpc5hr
3 Nov 23
Preliminary proxy related to merger
5:11pm
8-K
EX-99.1
41l8vd
26 Oct 23
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
4:35pm
DEFA14A
8egct7cm
17 Oct 23
Additional proxy soliciting materials
4:32pm
DEFA14C
jsycwr
5 Oct 23
Additional information
4:48pm
DEFA14C
v0lrovvw
5 Oct 23
Additional information
4:45pm
DEFA14C
7e05skc1dscr qgg4
5 Oct 23
Additional information
4:40pm
DEFA14A
e7i5toyb7o0t k2op5vc
5 Oct 23
Additional proxy soliciting materials
9:07am
8-K
EX-2.1
v7lah97
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
cplzebdswwtuyl
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
xgow56wivgk
18 Sep 23
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
7:07am
8-K
EX-99.2
zvzmzawj t4077
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.1
tlh9euddoji sdw6j
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.3
oujtea
23 May 23
Regulation FD Disclosure
7:06am